A c c e p te d fo r p u b lic a tio n : M a y 2 0 0 3 E xtended-spectrum beta-lactamases (ESBLs) are enzymes that mediate resistance to extendedspectrum cephalosporins and monobactams. These enzymes are produced mainly by K lebsiella p n eu m o n ia e and E scherichia coli,1,2 although they have been detected in other organisms, including Salmonella species, Pseudomonas aeruginosa and other Enterobacteriaceae.3 ESBL-producing strains can survive in the hospital environm ent.4 O utbreaks due to the dissemination o f various ESBL-producing Enterobacteriaceae species in hospitals and other health care facilities have been reported. Boundaries between com m unity and hospital environm ents are becoming more blurred, however, and this trend will continue due to the shift towards shorter hospital stays, the provision o f more treatm ent at hom e (even o f patients w ith severe and complicated illnesses) and the use o f more shortstay surgical interventions. This may have consequences for the development o f resistance to antimicrobial drugs and the spread o f resistant strains in the com m unity.6
Materials and Methods
Isolates were collected from outpatient adult females w ith clinical evidence o f com m unity-acquired urinary tract infections (UTI) during the period January to June 2 0 0 1, in the Gaza Strip. U TIs were defined as the culture o f a single organism from a midstream urine specimen at 105 colony form ing units per milliliter.7 O nly one specimen per patient was processed. Identification and confirm ation o f E. coli isolates were done according to standard procedures.7 '9 T he susceptibility o f the isolates to twelve antimicrobial agents was determ ined by the Kirby-Bauer disk diffusion technique according to the N CC LS recom m endations.10 T he disks and concentrations o f the twelve antimicrobial agents that are com m only used for the treatm ent o f UTIs in our region were as follows: amoxycillin , tetracycline (30 IU), amikacin (30 pg), gentamicin (30 pg) and nitrofurantoin (300 pg). We measured resistance to cefpodoxime (10 pg) by disk diffusion, which has been studied as a screening m ethod for ESBL production using a sensitivity break point o f 21 m m . 3 T he Epsilometer test (E-test) m ethod was used for confirm ation o f ESBL production (AB Biodisk, Solna, Sweden). T he strips were used according to the m anufacturers instructions. A ratio o f 8 or greater for the ceftazidime to ceftazidime-clavulanic acid minimal inhibitory concentrations (MICs) and the cefotaxime to cefotaxime-clavulanic acid M IC s was considered ESBLpositive.11 T he E-test was also used for determ ining the M IC values o f the antimicrobial agents used in this study.
T he quality control check was perform ed once weekly, using the reference strains E. coli A TCC 25 922 and a betalactamase-producing E. coli A TCC 35 218 to check the results o f disks that contain a com bination o f beta-lactam antibiotics and a beta-lactamase inhibitor.
Results
Three hundred E. coli isolates were collected from outpatient females w ith a mean age o f 41.5 years (range 18 to 65 years). Forty-eight (16.0% ) o f the 300 E. coli isolates were sensitive to all the antimicrobial agents tested. T he remaining 252 (84.0% ) isolates showed different resistance patterns. Putative ESBL-production was observed in 11 (3.3%) o f the 300 E. coli isolates. All putative ESBLproducers were found to be resistant to cefpodoxime according to the disk diffusion test.
T he ratio o f M ICs for ceftazidime/ ceftazidimeclavulanic acid and cefotaxime/cefotaxime-clavulanic acid was greater than 8 for 11 isolates, which were considered ESBL-producers (Table 1) . M ost o f the isolates showed high resistance, especially to amoxycillin (11/11), cephalosporins (11/11) and gentamicin (9/11) ( Table  2 ). All the isolates, however, were completely sensitive to amoxycillin-clavulanic acid and nitrofurantoin. Resistance o f ESBL-positive isolates was confirmed by the E-test (data n ot shown). It was evident from the data that all ESBLproducers were resistant to four or more antimicrobial 
ESBL-e x ten d ed -sp ectru m b e ta-lactam a se, CTX-c e fo ta x im e , CTX-CLA-c e fo taxim e-c lav u lan ic acid, CAZ-c e fta zid im e , CAZ-CLAc e fta zid im e -c la v u la n ic acid
o f data collection. Also, the populations investigated may differ in various socio-demographical, socioeconomical, socio-epidemiological, and clinical parameters. M ost o f the isolates showed co-resistance to n o n beta-lactam antimicrobials, especially to cotrimoxazole, gentamicin, nalidixic acid and ciprofloxacin. However, they were completely sensitive to amoxycillin-clavulanic acid and nitrofurantoin. Therefore, we conclude that amoxycillin-clavulanic acid, nitrofurantoin and amikacin remain effective treatm ent options for E. coli.
This study showed that all ESBL-producing isolates were resistant to four or more antimicrobial agents and that 4 o f them (36.4% ) were resistant to nine agents. T he considerably high M IC values o f amoxycillin, cotrimoxazole, tetracycline, nalidixic acid, cephalexin and cefuroxime observed in this study reflect the extent o f the treatm ent problem for ESBL-producing isolates. Jett et al.16 observed that 65% o f ESBL-producing isolates were resistant to non-beta-lactam antimicrobials (cotrimoxazole, ciprofloxacin or gentamicin). In another finding, Livermore and Yuan 17 found th at 4 o f their 6 ESBL-positive isolates were resistant to m ost aminoglycosides.
O u r study clearly shows that infection w ith these highly resistant isolates, w hich is usually confined to the hospital, is now being acquired in the community. Thus, we recom m end continuous surveillance for ESBL-producing isolates in both hospitals and the community. This will be necessary for controlling the spread o f these isolates, w hich complicate the treatm ent o f com m unity acquired UTIs. 
Discussion
In our study, 11 (3.3%) o f 300 E. coli isolates were ESBL-producers. Greater and fewer percentages o f ESBL production have been reported worldwide by other investigators.3,11' 15 Similarities and differences on antimicrobial resistance may be due to different periods 
